Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines

Haveri, Anu; Ikonen, Niina; Savolainen-Kopra, Carita; Julkunen, Ilkka

doi:10.1016/j.vaccine.2020.11.041

Cited by 5 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bars indicating titers against the primary vaccine, secondary vaccine and heterologous strains are red, blue and grey respectively. (A) data obtained from Erlich et al, 2009 [48]; (B) data obtained from Khurana et al, 2014 [47]; (C,G) data obtained from Levine et al, 2019 [44]; (D) data obtained from Risi et al, 2011 [40]; (E) data obtained from Goji et al, 2008 [49]; (F) data obtained from Haveri et al, 2021 [54]. In panel (G), the homologous vaccination regime counterpart of panel (C) is displayed for direct comparison.…”

Section: Discussion Of the Datamentioning

confidence: 99%

“…In these aforementioned studies, data entries, in which split inactivated vaccines were assessed, were the most numerous (n = 3), representing about half of the whole dataset, followed by those from studies on subunit (n = 17) and whole inactivated (n = 12) vaccines. Additionally, two different vaccine types were used for the primary and secondary vaccination(s) in two studies [53,54]. These vaccine types were used without adjuvant or with one of the adjuvants previously discussed.…”

Section: Description Of the Datasetmentioning

confidence: 99%

See 1 more Smart Citation

Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review

Kok¹,

Fouchier²,

Richard³

2021

Vaccines

View full text Add to dashboard Cite

Avian influenza viruses from the A/H5 A/goose/Guangdong/1/1996 (GsGd) lineage pose a continuing threat to animal and human health. Since their emergence in 1997, these viruses have spread across multiple continents and have become enzootic in poultry. Additionally, over 800 cases of human infection with A/H5 GsGd viruses have been reported to date, which raises concerns about the potential for a new influenza virus pandemic. The continuous circulation of A/H5 GsGd viruses for over 20 years has resulted in the genetic and antigenic diversification of their hemagglutinin (HA) surface glycoprotein, which poses a serious challenge to pandemic preparedness and vaccine design. In the present article, clinical studies on A/H5 influenza vaccination strategies were reviewed to evaluate the breadth of antibody responses induced upon homologous and heterologous prime-boost vaccination strategies. Clinical data on immunological endpoints were extracted from studies and compiled into a dataset, which was used for the visualization and analysis of the height and breadth of humoral immune responses. Several aspects leading to high immunogenicity and/or cross-reactivity were identified, although the analysis was limited by the heterogeneity in study design and vaccine type used in the included studies. Consequently, crucial questions remain to be addressed in future studies on A/H5 GsGd vaccination strategies.

show abstract

Section: Discussion Of the Datamentioning

confidence: 99%

Section: Description Of the Datasetmentioning

confidence: 99%

Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review

Kok¹,

Fouchier²,

Richard³

2021

Vaccines

View full text Add to dashboard Cite

show abstract

“…This scenario becomes more problematic in case of the emergence of new pandemic strains for which the world’s population does not have any type of immunological coverage [ 6 ]. In order to overcome these hurdles, multiple strategies have been tested to generate new influenza vaccines: improvement of the performance of current vaccines with new adjuvants and alternative routes of vaccine administration [ 7 , 8 , 9 , 10 , 11 , 12 , 13 ], development of new recombinant antigens able to promote the elicitation of cross-neutralizing antibodies to generate sterilizing immunity against all influenza strains [ 14 , 15 , 16 , 17 , 18 , 19 , 20 ], and utilization of relatively conserved influenza antigens (e.g., nucleoprotein) capable of inducing strong T cell responses that display a high degree of cross-reactivity against various influenza strains, [ 13 , 21 , 22 , 23 , 24 ]. …”

Section: Introductionmentioning

confidence: 99%

“…development of new recombinant antigens able to promote the elicitation of cross-neutralizing antibodies to generate sterilizing immunity against all influenza strains [ 14 , 15 , 16 , 17 , 18 , 19 , 20 ], and…”

Section: Introductionmentioning

confidence: 99%

Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG

et al. 2023

View full text Add to dashboard Cite

Current influenza vaccines target highly variable surface glycoproteins; thus, mismatches between vaccine strains and circulating strains often diminish vaccine protection. For this reason, there is still a critical need to develop effective influenza vaccines able to protect also against the drift and shift of different variants of influenza viruses. It has been demonstrated that influenza nucleoprotein (NP) is a strong candidate for a universal vaccine, which contributes to providing cross-protection in animal models. In this study, we developed an adjuvanted mucosal vaccine using the recombinant NP (rNP) and the TLR2/6 agonist S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxyl-poly-ethylene-glycol (BPPcysMPEG). The vaccine efficacy was compared with that observed following parenteral vaccination of mice with the same formulation. Mice vaccinated with 2 doses of rNP alone or co-administered with BPPcysMPEG by the intranasal (i.n.) route showed enhanced antigen-specific humoral and cellular responses. Moreover, NP-specific humoral immune responses, characterized by significant NP-specific IgG and IgG subclass titers in sera and NP-specific IgA titers in mucosal territories, were remarkably increased in mice vaccinated with the adjuvanted formulation as compared with those of the non-adjuvanted vaccination group. The addition of BPPcysMPEG also improved NP-specific cellular responses in vaccinated mice, characterized by robust lymphoproliferation and mixed Th1/Th2/Th17 immune profiles. Finally, it is notable that the immune responses elicited by the novel formulation administered by the i.n. route were able to confer protection against the influenza H1N1 A/Puerto Rico/8/1934 virus.

show abstract

Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters

Shen,

Hao,

Wang

et al. 2023

Vaccine

View full text Add to dashboard Cite

Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines

Cited by 5 publications

References 51 publications

Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review

Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review

Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG

Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters

Contact Info

Product

Resources

About